KR101173230B1 - The components of anti-obesity and its modulation of allium tuberosum rottl. extracts and processed sulfur - Google Patents
The components of anti-obesity and its modulation of allium tuberosum rottl. extracts and processed sulfur Download PDFInfo
- Publication number
- KR101173230B1 KR101173230B1 KR1020110057615A KR20110057615A KR101173230B1 KR 101173230 B1 KR101173230 B1 KR 101173230B1 KR 1020110057615 A KR1020110057615 A KR 1020110057615A KR 20110057615 A KR20110057615 A KR 20110057615A KR 101173230 B1 KR101173230 B1 KR 101173230B1
- Authority
- KR
- South Korea
- Prior art keywords
- sulfur
- composition
- leek
- present
- fat
- Prior art date
Links
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 239000011593 sulfur Substances 0.000 title claims abstract description 61
- 229910052717 sulfur Inorganic materials 0.000 title claims abstract description 61
- 244000003377 Allium tuberosum Species 0.000 title abstract description 4
- 235000005338 Allium tuberosum Nutrition 0.000 title abstract description 4
- 230000003579 anti-obesity Effects 0.000 title 1
- 239000000284 extract Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 46
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 35
- 210000002966 serum Anatomy 0.000 claims abstract description 8
- 108010023302 HDL Cholesterol Proteins 0.000 claims abstract description 5
- 108010028554 LDL Cholesterol Proteins 0.000 claims abstract description 4
- 230000036541 health Effects 0.000 claims abstract description 3
- 238000008214 LDL Cholesterol Methods 0.000 claims abstract 2
- 240000006108 Allium ampeloprasum Species 0.000 claims description 49
- 235000005254 Allium ampeloprasum Nutrition 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 2
- 244000144972 livestock Species 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 241000192132 Leuconostoc Species 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 abstract description 14
- 235000020824 obesity Nutrition 0.000 abstract description 14
- 235000013305 food Nutrition 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 2
- 230000003908 liver function Effects 0.000 abstract description 2
- 235000009200 high fat diet Nutrition 0.000 description 35
- 210000004185 liver Anatomy 0.000 description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 235000005911 diet Nutrition 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- 230000000378 dietary effect Effects 0.000 description 7
- 235000021050 feed intake Nutrition 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 235000019750 Crude protein Nutrition 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 235000019784 crude fat Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 241000234282 Allium Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000010876 biochemical test Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012499 inoculation medium Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 235000019393 L-cystine Nutrition 0.000 description 2
- 239000004158 L-cystine Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 235000006439 Lemna minor Nutrition 0.000 description 1
- 244000242291 Lemna paucicostata Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000203 accumulation affect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013364 duck meat Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000021105 fermented cheese Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229940016409 methylsulfonylmethane Drugs 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 229940071182 stannate Drugs 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 비만 예방 및 개선용 조성물에 관한 것으로, 구체적으로 부추즙 동결건조물 및 법제유황을 포함하여 이루어지는 비만 예방 및 개선용 조성물에 관한 것이다.The present invention relates to a composition for preventing and improving obesity, and more particularly, to a composition for preventing and improving obesity comprising leek juice lyophilisate and legal sulfur.
비만은 일반적으로 섭취한 열량 중 소모하고 남은 부분이 지방으로 전환되어 체내의 여러 부분, 특히 피하조직이나 복강 내에 과도하게 축적되는 현상으로 과도한 축적은 정상적인 생리 및 생화학적 기능에 영향을 미친다. 세계보건기구(World Health Organization, WHO) 및 전 세계적으로 관절염 질환 및 심혈관계 질환 등의 질병 뿐만 아니라 정신건강에까지 영향을 미칠 수 있는 비만을 치료해야 하는 질병으로 인식하여 많은 관심이 모아지고 있다. 최근 비만을 치료하기 위한 지방의 흡수 및 소화를 저해하는 플라보노이드나 키토산, 지방의 축적을 억제하는 고추에 포함되어있는 캡사이신 및 녹차의 카테킨 등의 천연물을 활용한 기능성 식품의 소재 개발이 진행되고 있다.Obesity is generally a phenomenon in which the remaining portion of calories consumed is converted to fat and excessively accumulated in various parts of the body, especially the subcutaneous tissue or the abdominal cavity, and excessive accumulation affects normal physiological and biochemical functions. Attention has been drawn to the World Health Organization (WHO) and the world as a disease to treat obesity that can affect not only arthritis and cardiovascular diseases but also mental health. Recently, development of functional food materials using natural products such as flavonoids and chitosan that inhibit fat absorption and digestion for treating obesity, and capsaicin and catechin of green tea, which are contained in peppers that inhibit fat accumulation, is underway.
부추(Allium tuberosum rottl.)는 Allium 속에 속하는 식물로, 예로부터 우리나라에서는 부추의 독특한 향과 맛에 의해 나물로 애용되었다. 부추에는 같은 Allium 속에 속하는 마늘 및 양파 등에 함유되어있는 알릴(allyl) 화합물 등의 함 황 물질이 함유되어 있고, 클로로필과 식이섬유가 풍부하며, 항혈전 성분인 아데노신(adenosin)이 포함되어 있다.Leek ( Allium tuberosum rottl. ) Is a plant belonging to the genus Allium, and has been used as an herb by the unique aroma and taste of leek in Korea since ancient times. Leek contains sulfur-containing substances such as allyl compounds contained in garlic and onions belonging to the same Allium, and is rich in chlorophyll and dietary fiber, and contains adenosine (adenosin), an antithrombogenic component.
유황은 동양에서는 독성을 제거 한 후 지혈작용, 신경마비 등 질병의 처방제로 쓰여 왔고, 골다공증을 치료하는데 효능이 있다고 알려져 있으며, 독성을 제거한 법제유황에 대해서는 골 질환에 영향을 미친다는 연구가 보고되어 있다. 유황은 독성이 강하므로 부작용이 생길 위험이 크기 때문에 현재 미국 식품의약국에서 승인한 무독성인 천연식이유황(MSM, Methylsulfonylmethane)을 식품에 사용하고 있다. 현재 국내에서는 기능성 오리 고기를 생산하기 위해 유황과 한약재를 섞은 사료를 이용하여 유황오리를 사육하고 있으며, 돼지에게 식이유황을 급여하는 연구가 조금씩 이루어지고 있는 실정이다.
Sulfur has been used as a prescription for diseases such as hemostasis and nerve palsy after eliminating toxicity, and it is known to be effective in treating osteoporosis. have. Because sulfur is highly toxic, there is a high risk of side effects. Currently, non-toxic natural dietary sulfur (MSM, Methylsulfonylmethane) is used for food. At present, in order to produce functional duck meat, sulfur ducks are raised by using a mixture of sulfur and herbal medicine, and research on feeding dietary sulfur to pigs is being conducted little by little.
이에 본 발명자들은 상기와 같은 부추와 법제유황이 체지방 축적에 미치는 영향을 연구하게 되었고, 이의 결과 부추즙 동결건조물과 법제유황을 포함시킨 조성물을 제조하여 이를 섭취할 경우, 불필요한 체중 증가 및 체지방 축적이 억제되어 비만을 예방 및 개선할 수 있음을 확인하고, 본 발명을 완성하게 되었다.
Therefore, the present inventors have studied the effects of leek and legal sulfur on body fat accumulation, and as a result, when preparing a composition containing leek juice lyophilisate and legal sulfur, unnecessary weight gain and body fat accumulation are prevented. It was confirmed that it can be prevented and improved obesity, thereby completing the present invention.
따라서 본 발명의 주된 목적은 불필요한 체중 증가 및 체지방 축적을 억제하여 비만을 예방 및 개선할 수 있는 비만 예방 및 개선용 조성물을 제공하는데 있다.
Therefore, the main object of the present invention is to provide a composition for preventing and improving obesity that can prevent and improve obesity by inhibiting unnecessary weight gain and body fat accumulation.
본 발명의 한 양태에 따르면, 본 발명은 부추, 부추즙 또는 부추즙 동결건조물과 법제유황을 포함하여 이루어지는 비만 예방 및 개선용 조성물을 제공한다.According to an aspect of the present invention, the present invention provides a composition for preventing and improving obesity comprising leek, leek juice or leek lyophilisate and legal sulfur.
본 발명의 조성물에 있어서, 상기 부추를 그대로 사용할 수 있으나, 바람직하게는 부추를 분쇄하고 여과하여 제조한 부추즙을 사용하는 것이 좋고, 더욱 바람직하게는 부추를 분쇄하고 여과한 다음 수득한 부추즙을 동결건조시킨 부추즙 동결건조물을 사용하는 것이 좋다.In the composition of the present invention, the leek may be used as it is, but it is preferable to use the leek juice prepared by grinding and filtering the leek, more preferably the leek juice obtained after crushing and filtering the leek Freeze-dried leek juice is recommended to use.
본 발명의 조성물에 있어서, 상기 법제유황은 유황의 독성을 제거한 것으로, 백토석 등의 광물질을 숙성시킨 물에 유황을 첨가하고 숙성시켜 유황의 독성을 제거한 다음 독성이 제거된 유황을 분말화하여 제조할 수 있으며, 황 함량이 99.0% 이상인 것이 바람직하다. 상기 법제유황은 본 발명이 속하는 분야에서 통상의 지식을 가진 자라면 용이하게 제조 또는 입수할 수 있다.In the composition of the present invention, the legal sulfur is to remove the toxicity of sulfur, the sulfur is added to the water to mature aged minerals, such as clay, and aged to remove the toxicity of sulfur and then manufactured by powdering the sulfur removed toxicity The sulfur content is preferably 99.0% or more. The legal sulfur can be easily manufactured or obtained by those skilled in the art to which the present invention pertains.
본 발명의 조성물에 있어서, 상기 부추즙 동결건조물은 5 내지 20중량%로 포함되고, 상기 법제유황은 0.01 내지 0.2중량%로 포함되는 것이 바람직하며, 더욱 바라직하게는 상기 부추즙 동결건조물은 10중량%로 포함되고, 상기 법제유황은 0.87중량%로 포함되는 것이 좋다. 이는 동물실험 결과를 바탕으로 하여 정해진 것으로, 쥐를 기준으로 부추즙 동결건조물 및 법제유황의 황 함량이 30㎎/1마리/1일이 되도록 제조할 때 바람직한 첨가량의 범위이며, 상기 첨가량에 따라 제조하였을 때 비만 예방 및 개선 효과가 뛰어나다.In the composition of the present invention, the leek juice lyophilisate is included in 5 to 20% by weight, the sulfur of the formulation is preferably contained in 0.01 to 0.2% by weight, more preferably the leek lyophilisate is 10 It is included in the weight%, the legal sulfur is preferably included in 0.87% by weight. It is determined based on the results of animal experiments, and it is a range of the preferred amount when the sulfur content of leek juice lyophilisate and legal sulfur is prepared to be 30 mg / 1 horses / day, based on the mouse, It is excellent in preventing and improving obesity.
본 발명의 조성물은 체중을 감소시키고, 고환주위지방 및 신장주위지방의 축적을 억제하며, 혈액의 AST(aspartate aminotransferase) 수치를 낮추고, 간의 총 지질, 중성지방 및 총 콜레스테롤 수치를 낮추는 효과를 나타낸다.The composition of the present invention has the effect of reducing weight, inhibiting the accumulation of peritesticular and peripheral fat, lowering the blood aspartate aminotransferase (AST) levels, and lowering the total lipid, triglyceride and total cholesterol levels of the liver.
본 발명의 다른 양태에 따르면, 본 발명은 상기 조성물을 포함하는 비만 예방 및 개선용 건강기능식품을 제공한다.According to another aspect of the present invention, the present invention provides a dietary supplement for preventing and improving obesity comprising the composition.
본 발명의 또 다른 양태에 따르면, 본 발명은 상기 조성물을 포함하는 비만 예방 및 개선용 기능성가축사료를 제공한다.
According to another aspect of the present invention, the present invention provides a functional livestock feed for preventing and improving obesity comprising the composition.
본 발명의 조성물은 의약품 및 식품 등의 용도로 사용할 수 있다.The composition of the present invention can be used for applications such as pharmaceuticals and food.
이때, 본 발명에 따른 조성물은 식품의약안정청(KFDA)의 통상적인 약제학제 제제로의 제형화 기준 또는 건강보조식품의 제형 기준에 의거하여 제형화할 수 있으며, 구강 투여용으로 제형화하는 것이 바람직하다.At this time, the composition according to the present invention can be formulated based on the formulation standard of the Food and Drug Administration (KFDA) as a conventional pharmaceutical formulation or the standard of the formulation of dietary supplements, preferably formulated for oral administration. .
본 발명의 투여량은 투여대상의 상태, 투여 경로 및 투여 형태에 따라 조절될 수 있어 한정되지 않으며 본 발명의 분야에서 통상의 지식을 가진 자라면 자명하게 다양한 범위 내에서 사용할 수 있으나, 본 발명에서 실험을 통해 확인된 바에 의하면 유효량으로 체중 1㎏ 당 150㎎ 정도를 하루에 연속적 또는 간헐적으로 투여가 가능할 것으로 판단된다.The dosage of the present invention can be adjusted according to the condition, route of administration, and dosage form of the subject to be administered, and one of ordinary skill in the art can obviously use within various ranges, but in the present invention Through experiments, it was determined that an effective amount of 150 mg / kg body weight per day can be continuously or intermittently administered.
또한, 본 발명 조성물의 유효량을 기준으로, 본 발명의 조성물 그 자체 또는 식품화학적으로 허용된 담체를 혼합한 조성물을 기본식이소재(其本食餌素材)로 포함하는 식품을 제공하는데, 상기 식품은 식육가공품, 어육제품, 두부, 묵, 죽, 라면이나 국수 등의 면류, 간장, 된장, 고추장, 혼합장 등의 조미식품, 소스, 과자, 발효유나 치즈 등의 유가공품, 김치나 장아찌 등의 절임식품, 과실, 채소, 두유, 발효음료 등의 음료수의 식품에 포함하여 사용할 수 있다. 이는 본 발명의 분야에서 통상의 지식을 가진 자라면 자명한 사항으로 이의 구체적인 조리 방법이나 생산 방법의 기재는 생략하기로 한다. 또한 식품학적으로 허용된 담체는 약제학적으로 허용된 담체도 사용할 수 있다.
In addition, based on the effective amount of the composition of the present invention, there is provided a food comprising the composition of the present invention itself or a composition mixed with a food chemically acceptable carrier as a basic dietary material (其 本 食餌 素材), the food is meat Processed products, fish meat products, tofu, jelly, porridge, noodles such as ramen or noodles, seasoned foods such as soy sauce, miso, red pepper paste, mixed soy sauce, dairy products such as sauces, sweets, fermented milk or cheese, pickled foods such as kimchi and pickles, It can be used in the food of beverages such as fruits, vegetables, soy milk, fermented beverages. This is obvious to those skilled in the art of the present invention will not be described the specific cooking method or production method thereof. In addition, a pharmaceutically acceptable carrier may also be used as a pharmaceutically acceptable carrier.
이상 설명한 바와 같이, 본 발명에 따르면 본 발명의 조성물을 섭취할 경우 불필요한 체중 증가 및 체지방 축적이 억제되어 비만을 예방하거나 개선할 수 있으며, 혈청의 생화학 수치가 안정화되며, 간의 총 지질, 중성지방 및 총 콜레스테롤 수치를 낮추어 간 기능을 개선할 수 있다.
As described above, according to the present invention, when the composition of the present invention is ingested, unnecessary weight gain and body fat accumulation can be suppressed, obesity can be prevented or improved, serum biochemical levels are stabilized, liver total lipids, triglycerides and Lowering your total cholesterol can improve liver function.
도 1은 본 발명의 조성물, 일반식이, 고지방식이, 법제유황이 함유된 고지방식이, 발효부추즙 동결건조물 및 법제유황이 함유된 고지방식이에 따른 흰쥐의 고환주위지방(epididymal adipose tissue)의 무게를 측정하여 나타낸 그래프이다. a, b, c는 알파벳이 다른 경우 유의차(p<0.05)가 있다는 것을 의미하며, 모든 수치는 평균ㅁ표준편차(n=5)로 나타내었다(CON : 일반식이 사료, HFD : 고지방식이 사료, HS : 법제유황이 함유된 고지방식이 사료(고지방식이+법제유황), AS : 부추즙 동결건조물 및 법제유황이 함유된 고지방식이 사료(고지방식이+부추즙 동결건조물+법제유황), FAS : 발효부추즙 동결건조물 및 법제유황이 함유된 고지방식이 사료(고지방식이+발효부추즙 동결건조물+법제유황)).
도 2는 본 발명의 조성물, 일반식이, 고지방식이, 법제유황이 함유된 고지방식이, 발효부추즙 동결건조물 및 법제유황이 함유된 고지방식이에 따른 흰쥐의 신장주위지방(retroperitoneal fat)의 무게를 측정하여 나타낸 그래프이다. a, b는 알파벳이 다른 경우 유의차(p<0.05)가 있다는 것을 의미하며, 모든 수치는 평균±표준편차(n=5)로 나타내었다.
도 3은 본 발명의 조성물, 일반식이, 고지방식이, 법제유황이 함유된 고지방식이, 발효부추즙 동결건조물 및 법제유황이 함유된 고지방식이에 따른 흰쥐 간의 총 지질(total lipid) 수준을 측정하여 나타낸 그래프이다. a, b, c는 알파벳이 다른 경우 유의차(p<0.05)가 있다는 것을 의미하며, 모든 수치는 평균±표준편차(n=5)로 나타내었다.
도 4는 본 발명의 조성물, 일반식이, 고지방식이, 법제유황이 함유된 고지방식이, 발효부추즙 동결건조물 및 법제유황이 함유된 고지방식이에 따른 흰쥐 간의 총 콜레스테롤(total cholesterol) 수준을 측정하여 나타낸 그래프이다. a, b는 알파벳이 다른 경우 유의차(p<0.05)가 있다는 것을 의미하며, 모든 수치는 평균±표준편차(n=5)로 나타내었다.
도 5는 본 발명의 조성물, 일반식이, 고지방식이, 법제유황이 함유된 고지방식이, 발효부추즙 동결건조물 및 법제유황이 함유된 고지방식이에 따른 흰쥐 간의 중성지방(triglyceride)을 측정하여 나타낸 그래프이다. a, b, c는 알파벳이 다른 경우 유의차(p<0.05)가 있다는 것을 의미하며, 모든 수치는 평균±표준편차(n=5)로 나타내었다.Figure 1 is a composition of the present invention, dietary fat, high fat diet, high fat diet containing legal sulfur, fermented leek juice lyophilisate and high fat diet containing sulfur (epididymal adipose tissue) of rats It is a graph showing the weight of the measurement. a, b, c means that there is a significant difference (p <0.05) when the alphabet is different, and all the values are expressed as the mean standard deviation (n = 5) (CON: general diet, HFD: high fat diet). Forage, HS: High-fat dietary foods containing legal sulfur (high-fat diet + legal sulfur), AS: Leek lyophilized and high-fat diets containing legal sulfur (high fat diet + leek lyophilis + legal sulfur ), FAS: Fermented leek juice lyophilised and high-fat diets containing legal sulfur (high fat diet + fermented leek juice lyophilised + legal sulfur).
Figure 2 of the composition of the present invention, general diet, high fat diet, high fat diet containing legal sulfur, fermented leek juice lyophilized and high fat diet containing sulfur containing the retroperitoneal fat of rats It is a graph that measured the weight. a and b mean that there is a significant difference (p <0.05) when the alphabets are different, and all values are expressed as mean ± standard deviation (n = 5).
Figure 3 shows the total lipid levels of the liver according to the composition of the present invention, diet, high fat diet, high fat diet containing legal sulfur, fermented leek juice lyophilisate and high fat diet containing legal sulfur. It is a graph measured and shown. a, b, and c mean that there is a significant difference (p <0.05) when the alphabets are different, and all values are expressed as mean ± standard deviation (n = 5).
Figure 4 shows the total cholesterol level of the rat liver according to the composition of the present invention, the diet, high fat diet, high fat diet containing legal sulfur, fermented leek lyophilized and high fat diet containing legal sulfur It is a graph measured and shown. a and b mean that there is a significant difference (p <0.05) when the alphabets are different, and all values are expressed as mean ± standard deviation (n = 5).
Figure 5 is the composition of the present invention, the general diet, high fat diet, high fat diet containing legal sulfur, fermented leek juice freeze-dried and the high fat diet containing the sulfur to measure the triglycerides (triglyceride) between rats The graph shown. a, b, and c mean that there is a significant difference (p <0.05) when the alphabets are different, and all values are expressed as mean ± standard deviation (n = 5).
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.
Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, and the scope of the present invention is not to be construed as being limited by these examples.
실험예 1.Experimental Example 1
본 실험예는 본 발명의 조성물에 따른 체중감소 및 체지방감소 효과를 동물모델을 통해 확인하기 위한 것이다.This experimental example is for confirming the weight loss and body fat reduction effect according to the composition of the present invention through an animal model.
동물모델로는 흰쥐를 사용하였으며, 흰쥐가 섭취할 수 있도록 본 발명의 조성물 및 비교대상 조성물을 사료형태로 제조하였다.As an animal model, a rat was used, and the composition of the present invention and the comparative composition were prepared in a feed form so as to be consumed by the rat.
1-1. 부추즙 동결건조물 제조1-1. Leek juice lyophilisate manufacturing
부추를 녹즙기(Angel-juicer, 부산광역시 사하구)에 넣고 분쇄한 다음 거즈((주)대한위재상사, 대구광역시 서구)로 여과하여 부추즙을 제조하였고, 상기 부추즙과 Leuconostoc mensenteriodes 균주를 접종한 MRS 액체배지를 1:1 비율로 혼합한 다음 동결건조기기(Ilshin Lab. MCFD 8510, 경기도 수원시)로 동결건조시켰다. 균주 접종 배지를 혼합하는 것은 부추즙을 발효하여 제조한 사료와 비교하기 위한 것으로 균주 접종 배지를 혼합하여 조성하였지만, 배양 및 발효 단계를 거치지 않고 동결건조시킨 것이다.The leek was put in a green juice (Angel-juicer, Saha-gu, Busan) and pulverized and filtered with gauze (Korea Daejae Co., Ltd., Seo-gu, Daegu Metropolitan City) to prepare leek juice. The liquid medium was mixed at a 1: 1 ratio and then lyophilized with a freeze-drying machine (Ilshin Lab. MCFD 8510, Suwon, Gyeonggi-do). Mixing the strain inoculation medium is to compare the feed prepared by fermenting the leek juice was prepared by mixing the strain inoculation medium, but lyophilized without going through the culture and fermentation step.
1-2. 발효부추즙 동결건조물 제조1-2. Fermented leek juice lyophilized preparation
상기 1-1에서와 동일한 방법을 사용하되, 균주 접종 배지를 혼합한 다음 30℃ 배양기에서 16시간 배양하는 단계를 추가하였다.Using the same method as in 1-1 above, the strain inoculation medium was mixed and then incubated for 16 hours in a 30 ℃ incubator was added.
1-3. 황 함량 분석1-3. Sulfur content analysis
상기 1-1 및 1-2에서 제조한 동결건조시킨 부추즙 및 발효부추즙의 황 함량 분석은 별다른 전처리 없이 EA 1110(ThermoQuest CE INSTRUMENTS, Italia)분석기기를 사용하여 측정하였다.The sulfur content analysis of the lyophilized leek juice and fermented leek juice prepared in 1-1 and 1-2 were measured using EA 1110 (ThermoQuest CE INSTRUMENTS, Italia) analyzer without any pretreatment.
이의 결과 표 1에 나타난 바와 같이, 발효한 것보다 발효하지 않은 것의 황 함량이 0.6%로 유의적으로(p<0.05) 높게 나타났다.As a result, as shown in Table 1, the sulfur content of the non-fermented ones was significantly higher (p <0.05) than that of the fermented ones.
* ATR : 부추즙 동결건조물, FATR : 발효부추즙 동결건조물* ATR: leek juice lyophilisate, FATR: fermented leek juice lyophilisate
1-4. 일반성분 분석1-4. General Ingredient Analysis
상기 1-1 및 1-2에서 제조한 동결건조시킨 부추즙 및 발효부추즙의 수분, 조단백질, 조지방, 조회분 및 조섬유의 양을 AOAC법으로 분석하였다. 수분은 105℃ 상압건조법, 회분은 550℃ 직접회화법, 조단백은 micro-Kjedahl법, 조지방은 soxhlet 추출법, 조섬유는 조섬유 추출장치(Fibertherm, Gerhardt, USA)를 사용하였고, 탄수화물은 100에서 수분, 조단백질, 조지방, 조회분 및 조섬유를 뺀 값으로 간주하였다.Moisture, crude protein, crude fat, crude ash and crude fiber of lyophilized leek juice and fermented leek juice prepared in 1-1 and 1-2 were analyzed by AOAC method. Moisture at 105 ° C atmospheric pressure drying, ash at 550 ° C direct ashing, crude protein micro-Kjedahl method, crude fat soxhlet extraction method, crude fiber crude fiber extractor (Fibertherm, Gerhardt, USA), carbohydrate at 100, moisture, crude protein , Crude fat, crude ash and crude fiber were subtracted.
이의 결과 표 2에 나타난 바와 같이, 발효하지 않은 것이 발효한 것에 비해 조단백과 조지방이 유의적으로(p<0.05) 높게 나타났다.As shown in Table 2, crude protein and crude fat were significantly higher (p <0.05) than those that were not fermented.
* 모든 수치는 평균±표준편차로 나타내었다.* All values are expressed as mean ± standard deviation.
* a, b : 알파벳이 다른 경우 유의차(p<0.05)가 있다는 것을 의미한다.* a, b: If the alphabet is different, it means that there is a significant difference (p <0.05).
* NS : 유의성이 없다는 것을 의미한다.NS means no significance.
1-5. 본 발명의 조성물에 따른 사료 제조1-5. Feed preparation according to the composition of the present invention
상기 1-1에서 제조한 동결건조물 100g에 법제유황 0.87g 및 고지방식이로 카제인(casein) 209.6g, 설탕(sucrose) 181.1g, 포도당(dextrose) 104.8g, 옥수수전분(corn starch) 76.3g, 셀룰로오스(cellulose) 52.4g, 콩기름(soybean oil) 26.2g, 돼지기름(lard) 186.0g, 미네랄 혼합물 47.2g, 비타민 혼합물 10.5g, L-cystine 3.1g, 콜린 중주석산염(choline bitartrate) 2.1g을 혼합하여 고지방식이+부추즙 동결건조물+법제유황으로 구성된 사료를 제조하였다(표 3의 AS).To 100 g of the lyophilisate prepared in 1-1, 0.87 g of legal sulfur and 209.6 g of casein in high fat diet, 181.1 g of sucrose, 104.8 g of glucose (dextrose), 76.3 g of corn starch, 52.4 g of cellulose, 26.2 g of soybean oil, 186.0 g of lard, 47.2 g of mineral mixture, 10.5 g of vitamin mixture, 3.1 g of L-cystine, 2.1 g of choline bitartrate By mixing, a diet consisting of high fat diet + leek lyophilisate + formulation sulfur was prepared (AS of Table 3).
사료는 (주)피드랩(경기도 하남시)에 의뢰하여 제조하였다.The feed was prepared by Feedlab Co., Ltd. (Hanam City, Gyeonggi-do).
1-6. 발효부추즙 동결건조물 및 법제유황이 포함된 사료 제조1-6. Preparation of Fermented Leek Juice Lyophilized and Containing Sulfur
상기 1-5에서와 동일한 방법을 사용하되, 동결건조물을 상기 1-2에서 제조한 것을 사용하여 고지방식이+발효부추즙 동결건조물+법제유황으로 구성된 사료를 제조하였다(표 3의 FAS).Using the same method as in the above 1-5, using a lyophilisate prepared in 1-2 above was prepared a feed consisting of high fat diet + fermented leek juice lyophilisate + formulation sulfur (FAS in Table 3).
사료는 (주)피드랩(경기도 하남시)에 의뢰하여 제조하였다.The feed was prepared by Feedlab Co., Ltd. (Hanam City, Gyeonggi-do).
1-7. 일반식이, 고지방식이 및 법제유황+고지방식이 사료 제조1-7. Preparation of Dietary, High-Fat, and Legal Sulfur + High-Fat Diets
비교실험을 위해 일반식이 사료(표 3의 CON), 고지방식이 사료(표 3의 HFD) 및 법제유황이 함유된 고지방식이(고지방식이+법제유황, 표 3의 HS)를 아래 표 3과 같이 제조하였다.For comparison experiments, dietary diets (CON in Table 3), high-fat diets (HFD in Table 3), and high-fat diets (high-fat diet + sulfur in table 3, HS in Table 3) containing legal sulfur are shown in Table 3 below. It was prepared as follows.
사료는 (주)피드랩(경기도 하남시)에 의뢰하여 제조하였다.The feed was prepared by Feedlab Co., Ltd. (Hanam City, Gyeonggi-do).
* ATR : 부추즙 동결건조물, FATR : 발효부추즙 동결건조물, CON : 일반식이 사료, HFD : 고지방식이 사료, HS : 법제유황이 함유된 고지방식이 사료(고지방식이+법제유황), AS : 부추즙 동결건조물 및 법제유황이 함유된 고지방식이 사료(고지방식이+부추즙 동결건조물+법제유황), FAS : 발효부추즙 동결건조물 및 법제유황이 함유된 고지방식이 사료(고지방식이+발효부추즙 동결건조물+법제유황)* ATR: leek juice lyophilisate, FATR: fermented leek juice lyophilisate, CON: general dietary feed, HFD: high-fat diet, HS: high-fat diet containing staple sulfur (high-fat diet + sulfur), AS : High-fat diet containing leek lyophilisate and legal sulfur (high fat diet + leek lyophilisate + legal sulfur), FAS: High-fat diet containing fermented leek juice and legal sulfur (high fat diet + Fermented leek juice lyophilized + legal sulfur)
1-8. 동물실험1-8. Animal experiment
실험동물로 5주령 Wister rat 수컷 흰쥐를 구입(중앙실험동물, 서울특별시 서초구)하여 사용하였고, 1주간 기본식이를 지급하여 적응시키고, 무작위로 6마리씩 5개의 군으로 분리하여 6주간 실험하였다. 상기 1-5 내지 1-7에서 제조한 각각의 사료를 1개의 실험군에 제공하되, 한마리당 하루에 20g씩 섭취하도록 하였고, 음수는 자유롭게 섭취할 수 있도록 하였다. 동물사육실은 온도와 습도를 유지하고, 12시간 간격으로 명암을 조절하였다.Five week-old Wister rat male rats were purchased (Central Experimental Animal, Seocho-gu, Seoul) and used as a basic diet for one week, and six animals were randomly divided into five groups for six weeks. Each of the feeds prepared in 1-5 to 1-7 were provided to one experimental group, but each was ingested 20g per day, and the negative water was freely ingested. Animal breeding room was kept temperature and humidity, and the contrast was adjusted every 12 hours.
1-9. 실험동물의 체중측정1-9. Weight Measurement of Laboratory Animals
1주일 간격으로 저울(Adventurer AR2140, OHAUS crop, USA)을 사용하여 각 실험동물의 체중을 측정하였다.The weight of each experimental animal was measured using a balance (Adventurer AR2140, OHAUS crop, USA) at weekly intervals.
1-10. 사료섭취량 및 칼로리섭취량 계산1-10. Feed intake and calorie intake calculation
사료 섭취량(g)은 전날 급여량(g)에서 다음날 잔여량(g)을 뺀 값(g)으로 하였고, 칼로리섭취량은 사료섭취량과 사료의 칼로리를 곱한 값으로 하였다.The feed intake (g) was calculated by subtracting the remaining amount (g) from the previous day's feed (g) and the calorie intake was the product of the feed intake and the calorie of the feed.
1-11. 장기중량 측정1-11. Long-term weight measurement
각 실험동물의 비장, 간장, 신장, 신장주위지방 및 고환주위지방을 적출하여 무게를 측정하였고, 간장은 적출 후 -80℃에서 보관하였다.The weights of the spleen, liver, kidney, peri-renal fat and peritesticular fat of each experimental animal were measured and weighed. The liver was stored at -80 ° C after extraction.
1-12. 혈청 생화학적 검사1-12. Serum biochemical test
실험 종료 후 각 실험동물의 후대 정맥에서 혈액을 채혈하였으며, 각 혈액을 3,000rpm에서 15분간 원심분리 한 후, 혈청을 분리하여 -20℃에서 냉동 보관하였고, 총 콜레스테롤(Total cholesterol), 트리글리세리드(triglyceride), HDL, LDL, AI(Atherogenic Index), AST(Aspartate aminotransferase), ALT(Alanine aminotransferase), 포도당(Glucose)의 농도를 측정하였다. AI(Atherogenic Index)는 ((total-C)-(HDL-C))/HDL-C로 계산하였다. 혈청 생화학적 검사는 (주)바이오톡스텍에 의뢰하여 검사하였다.After the experiment, blood was collected from the posterior vein of each animal, and each blood was centrifuged at 3,000 rpm for 15 minutes, and serum was separated and stored frozen at -20 ° C. Total cholesterol, triglyceride ), HDL, LDL, AI (Atherogenic Index), AST (Aspartate aminotransferase), ALT (Alanine aminotransferase), glucose (Glucose) concentrations were measured. AI (Atherogenic Index) was calculated as ((total-C)-(HDL-C)) / HDL-C. Serum biochemical test was conducted by Biotoxtech Co., Ltd.
1-13. 간 분석1-13. Liver analysis
1-13-1. 간의 총 지질(Total lipid)측정1-13-1. Total lipid measurement of liver
간의 총 지질은 Folch 등의 방법을 사용하여 추출하였다.Total lipids of the liver were extracted using the method of Folch et al.
50㎎의 간을 채취한 후 균질기(HS-30E, ㈜대한과학, 한국)에 넣고 증류수 3㎖을 첨가하여 균질 시킨 다음 클로로포름 7㎖를 첨가하였다. 원심분리 후 상층액과 부유물을 제거하고 N2 가스로 농축한 다음 무게를 측정하여 총 지질을 측정하였다.50 mg of liver was collected and placed in a homogenizer (HS-30E, Daehan Science, Korea) and homogenized by adding 3 ml of distilled water, followed by 7 ml of chloroform. After centrifugation, the supernatant and suspended solids were removed, concentrated with N2 gas, and weighed to determine total lipid.
1-13-2. 간의 총 콜레스테롤(Total cholesterol) 측정1-13-2. Determination of Total Cholesterol in the Liver
간의 총 콜레스테롤은 상기 1-13-1에서 N2 가스로 농축한 시료에 에탄올 2㎖를 첨가하여 용해한 후 키트 시약(아산제약, 한국)을 사용하여 측정하였다.The total cholesterol of the liver was measured by dissolving 2 ml of ethanol in the sample concentrated with N2 gas in 1-13-1 and using a kit reagent (Asan Pharmaceutical, Korea).
상기 에탄올을 첨가한 시료 20㎕에 효소액 3㎖를 넣고 37℃에서 5분간 방치한 다음 500nm에서 흡광도를 측정하였다.3 ml of enzyme solution was added to 20 µl of the ethanol-added sample, and the absorbance was measured at 500 nm after standing at 37 ° C. for 5 minutes.
1-13-3. 간의 중성지방(Triglyceride) 측정1-13-3. Triglyceride measurement of liver
상기 1-13-2에서 에탄올을 첨가한 시료 500㎕를 에펜도르프(Eppendorf) 튜브에 담고 에탄올을 제거한 다음, 트리톤 X-100(triton X-100)과 클로로포름을 1 대 1로 섞은 용액 50㎕를 넣고, 클로로포름 450㎕를 첨가하여 혼합한 다음 이 혼합액 20㎕에 키트시약의 효소액 3㎖를 첨가하고 37℃에서 15분간 방치한 후 550nm에서 흡광도를 측정하여 중성지방을 측정하였다.500 μl of the ethanol-added sample in 1-13-2 was placed in an Eppendorf tube, ethanol was removed, and 50 μl of a solution of Triton X-100 and chloroform in a 1: 1 ratio was added. After adding 450 µl of chloroform and mixing the mixture, 3 ml of the enzyme reagent of the kit reagent was added to 20 µl of the mixture, and the resultant was left at 37 ° C. for 15 minutes, and the absorbance was measured at 550 nm to measure neutral fat.
1-14. 통계1-14. statistics
모든 통계치는 SAS(Statistic Analytical Institute Cary NC, 1988)를 이용하여 분석하였으며, 평균 간의 유의성 검정(p<0.05)은 Tukey's Multiple Range Test 95%의 수준에서 유의적인 차이를 비교하였다.All statistics were analyzed using SAS (Statistic Analytical Institute Cary NC, 1988), and the significance test between the means (p <0.05) compared the significant difference at the level of 95% of Tukey's Multiple Range Test.
1-15. 결과1-15. result
1-15-1. 증체량 및 사료섭취량1-15-1. Weight gain and feed intake
각 실험군의 6주 동안의 체중 변화와 총 사료섭취량을 측정한 결과를 표 4에 나타내었다. 초기 체중은 181g으로 일정하였으나, 6주 후 체중 증가량은 HFD군에 비해 AS군에서 유의적으로(p<0.05) 감소하는 경향을 보였다. 총 사료섭취량에서는 전체적으로 유의적인 차이는 보이지 않았으나, HS군에서 낮은 경향을 보였다.Table 4 shows the results of measuring body weight change and total feed intake for 6 weeks in each experimental group. Initial body weight was constant at 181g, but after 6 weeks body weight gain decreased significantly (p <0.05) in AS group compared to HFD group. There was no significant difference in total feed intake, but it was low in the HS group.
* a, b, c : 알파벳이 다른 경우 유의차(p<0.05)가 있다는 것을 의미한다.* a, b, c: If the alphabet is different, it means that there is a significant difference (p <0.05).
* 모든 수치는 평균±표준편차(n=5)로 나타내었다.* All values are expressed as mean ± standard deviation (n = 5).
1-15-2. 장기 중량 측정1-15-2. Long-term weighing
각 실험군의 간, 신장, 비장, 고환주위지방, 신장주위지방의 중량 측정 결과를 표 5, 도 1 및 도 2에 나타내었다.The weight measurement results of liver, kidney, spleen, peritesticular fat and perirenal fat of each experimental group are shown in Table 5, FIGS. 1 and 2.
간의 무게에서는 전체적으로 유의적인 차이를 보이지 않았으며, 신장에서는 다른 군들은 유의적인 차이를 보이지 않았으나, FAS군이 유의적으로(p<0.05) 높게 나타났다. 비장에서도 CON과 HFD에 비해 FAS군에서 유의적으로(p<0.05) 높게 나타났다.There was no significant difference in the weight of the liver, and in the height, the FAS group was significantly higher (p <0.05). The spleen was significantly higher (p <0.05) in the FAS group than in the CON and HFD groups.
고환주위지방에서는 HFD군에 비해 HS군과 FAS군에서 유의적인 차이가 없었으나, AS군에서 유의적으로(p<0.05) 낮게 나타났으며, 신장주위지방에서는 HFD군에 비해 모든 군에서 신장주위지방의 무게가 유의적으로(p<0.05) 낮게 나타났다.In the testicular region, there was no significant difference in the HS and FAS groups compared to the HFD group, but it was significantly lower in the AS group (p <0.05). Fat weight was significantly lower (p <0.05).
* a, b, c : 알파벳이 다른 경우 유의차(p<0.05)가 있다는 것을 의미한다.* a, b, c: If the alphabet is different, it means that there is a significant difference (p <0.05).
* 모든 수치는 평균±표준편차(n=5)로 나타내었다.* All values are expressed as mean ± standard deviation (n = 5).
1-15-3. 혈청 생화학 검사1-15-3. Serum biochemistry
각 실험군의 혈청 생화학적 검사 결과를 표 6 및 7에 나타내었다.Serum biochemical test results of each experimental group are shown in Tables 6 and 7.
ALT에서는 모든 군에서 유의적인 차이가 없었으나, AST의 결과에서는 HFD에 비해 HS, AS, FAS군에서 모두 유의적으로(p<0.05) 낮은 값을 나타냈으며, FAS군에서 유의적으로(p<0.05) 가장 낮은 값을 나타내었다. 혈당의 측정 결과 모든 군에서 유의적인 차이가 없었으며, HS군과 AS군 사이에서 유의적인(p<0.05) 차이가 나타났다. LDL-C의 결과 HFD군에 비해 처리군 모두 유의적 차이는 없었으나, AS군과 FAS군에서 모두 낮아지는 경향을 보였다. AI 결과에서는 AS군에서 가장 낮은 값을 나타내었다.In ALT, there was no significant difference in all groups, but the results of AST were significantly lower in the HS, AS, and FAS groups (p <0.05) than in HFD, and significantly (p <) in the FAS group. 0.05) showed the lowest value. There was no significant difference in all groups, and there was a significant (p <0.05) difference between the HS and AS groups. The results of LDL-C showed no significant difference in the treated group compared to the HFD group, but decreased in both the AS and FAS groups. The AI result showed the lowest value in the AS group.
* a, b, c, d : 알파벳이 다른 경우 유의차(p<0.05)가 있다는 것을 의미한다.* a, b, c, d: If the alphabet is different, it means that there is a significant difference (p <0.05).
* 모든 수치는 평균±표준편차(n=5)로 나타내었다.* All values are expressed as mean ± standard deviation (n = 5).
* a, b, c, d : 알파벳이 다른 경우 유의차(p<0.05)가 있다는 것을 의미한다.* a, b, c, d: If the alphabet is different, it means that there is a significant difference (p <0.05).
* 모든 수치는 평균±표준편차(n=5)로 나타내었다.* All values are expressed as mean ± standard deviation (n = 5).
1-15-4. 간의 총 지질(Total lipid) 측정1-15-4. Total lipid measurement of liver
각 실험군의 간의 총 지질을 측정한 결과를 도 3에 나타내었다.The result of measuring the total lipid of the liver of each experimental group is shown in FIG.
총 지질의 양은 HFD군에 비해 모든 군에서 유의적으로(p<0.05) 낮게 나타났으며, AS 군에서 가장 낮은 값을 나타내었다.The amount of total lipid was significantly lower (p <0.05) in all groups than in the HFD group, and the lowest in the AS group.
1-15-5. 간의 총 콜레스테롤(Total cholesterol) 측정1-15-5. Determination of Total Cholesterol in the Liver
각 실험군의 간의 총 콜레스테롤을 측정한 결과를 도 4에 나타내었다.The result of measuring total cholesterol of each experimental group is shown in FIG.
HFD군에 비해 AS군과 FAS군에서 유의적으로(p<0.05) 낮은 값을 나타내었다.
The AS and FAS groups showed significantly lower values than the HFD group (p <0.05).
1-15-6. 간의 중성지방(Triglyceride) 측정1-15-6. Triglyceride measurement of liver
각 실험군의 간 중성지방을 측정한 결과를 도 5에 나타내었다.The result of measuring the liver triglyceride of each experimental group is shown in FIG.
HFD군에 비해 HS군은 유의적 차이는 없었으나, AS군과 FAS군에서 유의적으로(p<0.05) 낮은 값을 나타내었다.There was no significant difference in the HS group compared to the HFD group, but the AS and FAS groups showed significantly lower values (p <0.05).
Claims (5)
혈청 내 HDL-콜레스테롤의 농도를 높이고, LDL-콜레스테롤의 농도를 낮추는 것을 특징으로 하는 동맥경화 예방 및 개선용 조성물.The method of claim 1, wherein the composition
Atherosclerosis prevention and improvement composition, characterized in that to increase the concentration of HDL-cholesterol in the serum, and lower the concentration of LDL-cholesterol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110057615A KR101173230B1 (en) | 2011-06-14 | 2011-06-14 | The components of anti-obesity and its modulation of allium tuberosum rottl. extracts and processed sulfur |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110057615A KR101173230B1 (en) | 2011-06-14 | 2011-06-14 | The components of anti-obesity and its modulation of allium tuberosum rottl. extracts and processed sulfur |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101173230B1 true KR101173230B1 (en) | 2012-08-17 |
Family
ID=46887208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110057615A KR101173230B1 (en) | 2011-06-14 | 2011-06-14 | The components of anti-obesity and its modulation of allium tuberosum rottl. extracts and processed sulfur |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101173230B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150139153A (en) * | 2014-06-02 | 2015-12-11 | 달성군 | Butchu fermentated extract using Lactic acid bacteria sp. and anti-diabetic composition comprising the same |
-
2011
- 2011-06-14 KR KR1020110057615A patent/KR101173230B1/en not_active IP Right Cessation
Non-Patent Citations (2)
Title |
---|
Food Sci. Technol. Res., 15 (3), 343 ? 346, 2009* |
한국식품영양과학회지 36(1), 27-31, 2007* |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150139153A (en) * | 2014-06-02 | 2015-12-11 | 달성군 | Butchu fermentated extract using Lactic acid bacteria sp. and anti-diabetic composition comprising the same |
KR101722584B1 (en) * | 2014-06-02 | 2017-04-04 | 달성군 | Butchu fermentated extract using Lactic acid bacteria sp. and anti-diabetic composition comprising the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Friday et al. | Investigations on the nutritional and medicinal potentials of Ceiba pentandra leaf: A common vegetable in Nigeria | |
Hanan et al. | Utilization of Garden Cress Seeds (Lepidium sativum L.) as Natural Source of Protein and Dietary Fiber in Noodles. | |
Pandey et al. | Seaweeds—a potential source for functional foods | |
KR101256744B1 (en) | Hot sauce and process thereof | |
Dimov et al. | Improvement of antioxidant potential of wheat flours and breads by addition of medicinal plants. | |
CN101766274B (en) | Antioxidant functional food composition containing bamboo-leaves flavones | |
Niazi et al. | An overview: Date palm seed coffee, a functional beverage | |
Patel | Opuntia cladodes (nopal): Emerging functional food and dietary supplement | |
Seyed-Mostafa et al. | The effects of Persian shallot extract on the levels of some blood biochemical parameters in streptozotocin-induced diabetic rats | |
JP2005278478A (en) | Rebound preventing beverage and fat absorption restraining agent each containing post-heating fermented tea | |
KR20040024774A (en) | a compositions which is composed of a nature medicines suitable for a different physical condition by a blood type | |
KR101173230B1 (en) | The components of anti-obesity and its modulation of allium tuberosum rottl. extracts and processed sulfur | |
JP2006347975A (en) | Oral composition for cardiovascular disease prophylaxis and amelioration | |
JP2007131605A (en) | Indefinite complaint-improving composition and food | |
KR20180075763A (en) | Composition comprising the ethanol extract of Portulacea oleracea for preventing and treating of Alcoholic liver damage | |
Tsafack et al. | Nutritional value of Raphia hookeri fruit, hematological properties of its powder and aqueous extract in a model of aluminum chloride inducing neurotoxicity by using rats | |
Khojah et al. | Fortification of macaroni with pomegranate peels as dietary fiber and natural antioxidant for the treatment of obesity and high cholesterol in rats | |
Mba et al. | Developments on the Bioactive Compounds and Food Uses of the Tubers: Colocasia esculenta (L) Schott (Taro) and Xanthosoma sagittifolium (L) Schott (Tannia) | |
Al Amrani et al. | Artichoke and health (food and medicine): A review | |
KR20190081582A (en) | Fermented product having an anti-obesity effect containing apigenin or naringenin as an active ingredient and a method for producing the same | |
Kopcekova et al. | The relationship between seeds consumption, lipid profile and body mass index among patients with cardiovascular diseases | |
Moustafa et al. | Protective effect of strawberry leaves against nephrotoxicity of male rats | |
KR101314917B1 (en) | Manufactuing method of functional noodles for relieving hangover | |
KR20120040890A (en) | Blueberry fermentation extract as an effective components for prevention and treatment of obesity | |
EL-Bushuty | Effect of artichoke leaves extract against potassium bromate induced renal injury in rats and its possibility adding in some edible salads |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150917 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160727 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |